Ken Nagata
Overview
Explore the profile of Ken Nagata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kataoka K, Ouchi A, Suwa Y, Hirano H, Yamaguchi T, Takamizawa Y, et al.
Eur J Surg Oncol
. 2024 Apr;
50(6):108354.
PMID: 38657376
Although phase III randomized controlled trials (RCTs) represent the most robust statistical approach for answering clinical questions, they require massive expenditures in terms of time, labor, and funding. Ancillary and...
2.
Nagata K, Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, et al.
BMJ Neurol Open
. 2023 Feb;
5(1):e000370.
PMID: 36727104
Background: This subcohort study of All Nippon AF In the Elderly (ANAFIE) Registry based on 33 275 elderly patients (aged ≥75 years) with non-valvular atrial fibrillation (NVAF) investigated the relationship...
3.
Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, et al.
J Cardiol
. 2022 Jul;
80(4):375-376.
PMID: 35779981
No abstract available.
4.
Yamadera M, Shinto E, Nagata K, Shiraishi T, Kajiwara Y, Mochizuki S, et al.
Int J Clin Oncol
. 2022 Jan;
27(4):756-764.
PMID: 35091826
Background: In colorectal cancer, tumor budding is highlighted as both a prognostic indicator and a predictor of chemosensitivity. However, tumor budding has a serious drawback because of unattainable preoperative assessment,...
5.
Ao T, Mochizuki S, Kajiwara Y, Yonemura K, Shiraishi T, Nagata K, et al.
Int J Cancer
. 2022 Jan;
150(10):1706-1721.
PMID: 35080810
The tumor microenvironment plays a key role in cancer aggressiveness. Desmoplastic reaction (DR), morphologically classified as Mature, Intermediate and Immature types, has previously been shown to be highly prognostic in...
6.
Einama T, Yamagishi Y, Takihata Y, Suzuki T, Yamasaki T, Hirose Y, et al.
Biomark Res
. 2021 Oct;
9(1):78.
PMID: 34715925
The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the...
7.
Nagata K, Shinto E, Ueno H
Ann Surg Oncol
. 2021 Aug;
28(13):8587-8588.
PMID: 34346021
No abstract available.
8.
Nagata K, Shinto E, Shiraishi T, Yamadera M, Kajiwara Y, Mochizuki S, et al.
Ann Surg Oncol
. 2021 Jul;
28(13):8579-8586.
PMID: 34318385
Background: Mesothelin (MSLN) is a cell-surface glycoprotein present on mesothelial cells; its expression in several epithelial cancers generally portends an unfavorable prognosis. We investigated MSLN as a surrogate chemopredictive biomarker...
9.
Shiraishi T, Shinto E, Yamadera M, Nagata K, Tsuda H, Mochizuki S, et al.
Oncotarget
. 2020 Nov;
11(43):3807-3817.
PMID: 33196692
Mesothelin (MSLN) is a cell surface glycoprotein that is normally expressed in the mesothelial cells but highly expressed in several malignant tumors, where the high expression is generally associated with...
10.
Uchiyama S, Hoshino T, Charles H, Kamiyama K, Nakase T, Kitagawa K, et al.
J Atheroscler Thromb
. 2020 Sep;
28(6):656-664.
PMID: 32938836
Aims: We have previously reported 5-year follow-up data on the TIAregistry.org, an international prospective cohort in patients with transient ischemic attack (TIA) or minor stroke. We conducted a Japanese subgroup...